Evidence map›Paper›PMID 35337131›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin-HDAC Inhibitor Hybrids as Multitarget Drugs.

Lukas von Bredow, Thomas Martin Schäfer, Julian Hogenkamp, Maik Tretbar, Daniel Stopper, Fabian B Kraft, Julian Schliehe-Diecks, Andrea Schöler, Arndt Borkhardt, Sanil Bhatia and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Lukas von BredowMedical Faculty, Institute for Drug Discovery, Leipzig University, 04103 Leipzig, Germany.
Thomas Martin SchäferInstitut für Tropenmedizin, Eberhard Karls Universität Tübingen, 72074 Tübingen, Germany.
Julian HogenkampDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany.ORCID 0000-0002-7828-6593
Maik TretbarMedical Faculty, Institute for Drug Discovery, Leipzig University, 04103 Leipzig, Germany.ORCID 0000-0003-3819-7358
Daniel StopperDepartment of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany.
Fabian B KraftDepartment of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany.
Julian Schliehe-DiecksDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany.
Andrea SchölerMedical Faculty, Institute for Drug Discovery, Leipzig University, 04103 Leipzig, Germany.
Arndt BorkhardtDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany.
Sanil BhatiaDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany.ORCID 0000-0001-6494-7744
Jana HeldInstitut für Tropenmedizin, Eberhard Karls Universität Tübingen, 72074 Tübingen, Germany.ORCID 0000-0002-7970-1429
Finn K HansenDepartment of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany.ORCID 0000-0001-9765-5975
Heinrich Heine University Düsseldorf · DELeipzig University · DEUniversity of Bonn · DEGerman Center for Infection Research · DEUniversity of Tübingen · DE

Funding

Deutsche Forschungsgemeinschaft 270650915Deutsche Forschungsgemeinschaft HA 7783/1-2Deutsche Forschungsgemeinschaft HE 7607/1-2
6 · The paper itself

Abstract

Artemisinin-based combination therapies (ACTs) are the gold standard for the treatment of malaria, but the efficacy is threatened by the development of parasite resistance. Histone deacetylase inhibitors (HDACis) are an emerging new class of potential antiplasmodial drugs. In this work, we present the design, synthesis, and biological evaluation of a mini library of dihydroartemisinin-HDACi hybrid molecules. The screening of the hybrid molecules for their activity against selected human HDAC isoforms, asexual blood stage

Indexed as

artemisininhistone deacetylasemultitarget drugs

Identifiers

PMID35337131
PMCPMC8952208
OpenAlexW4220675992

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.